Long-term care of patients with interstitial cystitis is appreciated  by Kuo, Hann-Chorng
at SciVerse ScienceDirect
Urological Science 24 (2013) 1Contents lists availableUrological Science
journal homepage: www.urol-sci .comEditorial
Long-term care of patients with interstitial cystitis is appreciatedInterstitial cystitis/bladder pain syndrome (IC/BPS) is a syn-
drome of mystery in urology. IC/BPS is characterized by bladder
pain associated with urgency to urinate frequent urination, noctu-
ria, dysuria, and sterile urine. IC/BPS is diagnosed based on the ﬁnd-
ings of symptomatology and urological analysis including the
identiﬁcation of characteristic cystoscopic features after hydrodis-
tention under anesthesia.1 In this issue of Urological Science, Wu
et al2 followed up 54 patients with cystoscopic-conﬁrmed IC/BPS
for a median period of 30.6 months, of which 98.1% of patients
had received multiple treatment regimens including oral medica-
tion, intravesical heparin instillations, and hydrodistention.
Although only 14 patients had an increase of global response
assessment by two points, the overall positive perception rate
was 81.6%. The authors concluded that long-term, continual treat-
ments for IC/BPS are appreciated by most patients.
In this study, the authors reported that all patients had pain and
pressure over the bladder or pelvic region. However, in clinical
experience, pain is only experienced in 33.5% of the patients with
IC/BPS.3 It is possible that the authors did not include patients
with bladder oversensitivity without pain for diagnostic cysto-
scopic hydrodistention. Although some of the patients might not
experience pain at all, a small functional bladder capacity often rai-
ses an early suspicion about IC/BPS.4
The diagnosis of IC/BPS remains unclear and should be based on
the exclusion of other diseases. Current treatment methods are
based on the possible etiologies of IC/BPS, including (1) a postinfec-
tion autoimmune process, (2) mast cell activation induced by
inﬂammation, toxins, or stress, (3) urothelial dysfunction and
increased permeability of the urothelium, or (4) neurogenic inﬂam-
mation. IC/BPS is also associated with a number of lifestyle and psy-
chosocial correlates. This suggests that the treatment of patients
with IC/BPS may beneﬁt from a multifaceted approach of
combining medical, psychological, and cognitive treatment in addi-
tion to controlling the dysfunctional epithelium.5
By far, administration of intravesical heparin and hyaluronic
acid continue to remain as the treatment of choice for early IC/
BPS based on the published reports.6–8 However, as commented
by the authors, the placebo effect should be weighed and random-
ized, double-blind trials should be undertaken to demonstrate the
actual therapeutic effects of these therapeutic modalities.
Although the action mechanism of onabotulinumtoxinA injection
for IC/BPS remains undetermined, positive response and long-
term cure of IC/BPS have been reported recently.9 Combination
therapies of hydrodistention, antihistamines, analgesics, and anti-
cholinergics might be beneﬁcial in addition to intravesical treat-
ments. As the authors addressed, we seldom cure but we always
care for patients with IC/BPS. With efforts in the early diagnosis1879-5226  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
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Opand treatment, long-term therapy is needed for a better cure rate
for IC/BPS.
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